
自引率: 11.2%
被引量: 4838
通过率: 暂无数据
审稿周期: 暂无数据
版面费用: 暂无数据
国人发稿量: 24
投稿须知/期刊简介:
Bipolar Disorders is an international journal that publishes all research of relevance for the basic mechanisms, clinical aspects, or treatment of bipolar disorders. It intends to provide a single international outlet for new research in this area. Papers on biochemistry, physiology, neuropsychopharmacology, neuroanatomy, neuropathology, genetics, brain imaging, epidemiology, phenomenology, clinical aspects, and therapeutics of bipolar disorders will be considered. In particular, papers that provide leads for development of new therapeutic strategies for these disorders are specially welcome. The journal will also consider submissions on the topics of schizoaffective disorders, and recurrent depressive disorders, as these are cyclic disorders with areas of overlap with bipolar disorders. The journal will accept full-length research papers, brief reports, invited editorials, news and views, review articles, letters to the editor, rapid communications, and case reports of unusual interest. A special feature will be an international grand rounds section in which cases of special relevance will be discussed. The journal will be committed to rapid review and publication on manuscripts. In case of studies of unusual novelty and importance for the field, the review process will be completed within 30 days, for publication as rapid communications in the next issue of the journal.
期刊描述简介:
Bipolar Disorders is an international journal that publishes all research of relevance for the basic mechanisms, clinical aspects, or treatment of bipolar disorders. It intends to provide a single international outlet for new research in this area. Papers on biochemistry, physiology, neuropsychopharmacology, neuroanatomy, neuropathology, genetics, brain imaging, epidemiology, phenomenology, clinical aspects, and therapeutics of bipolar disorders will be considered. In particular, papers that provide leads for development of new therapeutic strategies for these disorders are specially welcome. The journal will also consider submissions on the topics of schizoaffective disorders, and recurrent depressive disorders, as these are cyclic disorders with areas of overlap with bipolar disorders. The journal will accept full-length research papers, brief reports, invited editorials, news and views, review articles, letters to the editor, rapid communications, and case reports of unusual interest. A special feature will be an international grand rounds section in which cases of special relevance will be discussed. The journal will be committed to rapid review and publication on manuscripts. In case of studies of unusual novelty and importance for the field, the review process will be completed within 30 days, for publication as rapid communications in the next issue of the journal.
-
A 6-month, prospective, randomized controlled trial of customized adherence enhancement versus a bipolar-specific educational control in poorly adherent adolescents and young adults living with bipolar disorder.
Few studies have addressed medication adherence in adolescents and young adults (AYAs) with bipolar disorder (BD). This 6-month prospective randomized-controlled trial (RCT) tested customized adherence enhancement for adolescents and young adults (CAE-AYA), a behavioral intervention for AYAs versus enhanced treatment as usual (ETAU). Inclusion criteria were AYAs age 13-21 with BD type I or II with suboptimal adherence defined as missing ≥20% of medications. Assessments were conducted at Screening, Baseline, and weeks 8, 12 and 24. Primary outcome was past 7 day self-reported Tablets Routine Questionnaire (TRQ) validated by electronic pillbox monitoring (SimpleMed). Symptom measures included the Hamilton Depression Rating Scale (HAM-D) and Young Mania Rating Scale (YMRS). The mean sample age (N = 36) was 19.1 years (SD = 2.0); 66.7% (N = 24) female, BD Type I (81%). The mean missed medication on TRQ for the total sample was 35.4% (SD = 28.8) at screening and 30.4% (SD = 30.5) at baseline. Both CAE-AYA and ETAU improved on TRQ from screening to baseline. Baseline mean missed medication using SimpleMed was 51.6% (SD = 38.5). Baseline HAM-D and YMRS means were 7.1 (SD = 4.7) and 6.0 (SD = 7.3), respectively. Attrition rate at week 24 was 36%. Baseline to 24-week change on TRQ, adjusting for age, gender, educational level, living situation, family history, race, and ethnicity, showed improvement favoring CAE-AYA versus ETAU of 15%. SimpleMed interpretation was limited due to substantial missing data. There was a significant reduction in depression favoring CAE-AYA. CAE-AYA may improve adherence in AYAs with BD, although conclusions need to be made cautiously given study limitations. ClinicalTrials.gov identifier: NCT04348604.
被引量:- 发表:1970
-
Postpartum rage attacks in a female with bipolar II disorder and obsessive-compulsive disorder: Diagnostic and treatment challenges.
被引量:- 发表:1970
-
A case of delirious mania in the context of concurrent cardiac comorbidities and autonomic instability.
被引量:- 发表:1970
-
Case report: Manic-like symptoms mimicking early-onset bipolar disorder in a case of neuropsychiatric lupus.
被引量:- 发表:1970
-
Utilizing long-acting injectables to address noncompliance among adolescents diagnosed with bipolar disorder.
被引量:- 发表:1970